Genetic testing for lung cancer

Clinical research indicated that non-small cell lung cancer (NSCLC) is triggered by certain oncogenic driver genes, including AKT1,ALK, BRAF, EGFR,HER2, KRAS, MEK1, MET, NRAS, PIK3CA, RET and ROS1. The structural alterations (mutation, overexpression or rearrangement) of these tumorigenic genes (cells) may trigger and promote tumor development. Targeted cancer therapy is a method specific for clearly defined oncogenic cancer cells. This remedy is realized by specific inhibition of the proliferation of tumor cells via targeted medicine that inhibits these tumorigenesis genes at molecular level, while killing oncogenic cancer cells, they do no harm to normal tissues and cells.